期刊
HARVARD REVIEW OF PSYCHIATRY
卷 26, 期 6, 页码 320-339出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/HRP.0000000000000179
关键词
biomarkers; ketamine; neuroimaging; magnetic resonance imaging; magnetoencephalogram; positron emission tomography; treatment-resistant depression
类别
资金
- National Institute of Mental Health [K23-MH107776, R01MH102279]
- Brain and Behavior Research Foundation
- MGH Executive Committee on Research
- Louis V. Gerstner Family Foundation
- Depressive and Bipolar Disorder Alternative Treatment Foundation
- International OCD Association
- Tourette Syndrome Association
- NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH102279, K23MH107776] Funding Source: NIH RePORTER
Major depressive disorder (MDD) is one of the most prevalent conditions in psychiatry. Patients who do not respond to traditional monoaminergic antidepressant treatments have an especially difficult-to-treat type of MDD termed treatment-resistant depression. Subanesthetic doses of ketamine-a glutamatergic modulator-have shown great promise for rapidly treating patients with the most severe forms of depression. As such, ketamine represents a promising probe for understanding the pathophysiology of depression and treatment response. Through neuroimaging, ketamine's mechanism may be elucidated in humans. Here, we review 47 articles of ketamine's effects as revealed by neuroimaging studies. Some important brain areas emerge, especially the subgenual anterior cingulate cortex. Furthermore, ketamine may decrease the ability to self-monitor, may increase emotional blunting, and may increase activity in reward processing. Further studies are needed, however, to elucidate ketamine's mechanism of antidepressant action.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据